Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of NUT carcinoma and other cancers: results of a phase I/II open-label, dose escalation study.
Sign Up to like & getrecommendations! Published in 2021 at "International journal of cancer"
DOI: 10.1002/ijc.33861
Abstract: Molibresib is an orally bioavailable, selective, small molecule BET protein inhibitor. Results from a first time in human study in solid tumors resulted in the selection of a 75 mg once daily dose of the besylate… read more here.
Keywords: clinical activity; safety; molibresib; cancer ... See more keywords
Correlates of immune and clinical activity of novel cancer vaccines.
Sign Up to like & getrecommendations! Published in 2018 at "Seminars in Immunology"
DOI: 10.1016/j.smim.2018.04.001
Abstract: Cancer vaccines are solely meant to amplify the pool of type 1 cytokine oriented CD4+ and CD8+ T cells that recognize tumor antigen and ultimately foster control and destruction of a growing tumor. They are… read more here.
Keywords: cancer vaccines; clinical activity; cancer; therapeutic cancer ... See more keywords
Clinical activity after fingolimod cessation: disease reactivation or rebound?
Sign Up to like & getrecommendations! Published in 2018 at "European Journal of Neurology"
DOI: 10.1111/ene.13694
Abstract: There is debate as to whether the apparent rebound after fingolimod discontinuation is related to the discontinuation itself or whether it is due to the natural course of highly active multiple sclerosis (MS). Our aim… read more here.
Keywords: reactivation rebound; clinical activity; activity fingolimod; fingolimod cessation ... See more keywords
AB0494 Increased levels of interferon alpha and interleukin-10 as clinical activity biomarkers in systemic lupus erythematous patients
Sign Up to like & getrecommendations! Published in 2017 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2017-eular.4180
Abstract: Background Systemic lupus erythematous (SLE) is an autoimmune disease characterized by immune system disruption, including deregulation of cytokine production. Interferon alpha (INF1A) is considered a key molecule in SLE etiopathogenesis, being responsible of the differentiation… read more here.
Keywords: blys; il10 blys; clinical activity; inf1a ... See more keywords
AB0517 CORRELATION BETWEEN PATIENT-REPORTED OUTCOMES OF HEALTH-RELATED QUALITY OF LIFE AND CLINICAL ACTIVITY IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS
Sign Up to like & getrecommendations! Published in 2019 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2019-eular.5661
Abstract: Background: Patient-Reported Outcomes (PROs) allow us to know the way the disease could affect patients, and maybe could not be detected in clinical measures. Among these, PROs of health-related quality of life (PRO-QL) represents patient… read more here.
Keywords: clinical activity; health; quality life; correlation ... See more keywords
Association of homogeneous inflamed gene signature with a better outcome in patients with metastatic melanoma treated with MAGE-A3 immunotherapeutic
Sign Up to like & getrecommendations! Published in 2018 at "ESMO Open"
DOI: 10.1136/esmoopen-2018-000384
Abstract: Purpose This study assessed clinical activity, safety and immunogenicity of MAGE-A3 immunotherapeutic in patients with MAGE-A3-positive metastatic melanoma. Patients and methods In this open-label, multicentre, uncontrolled, Phase II study (ClinicalTrials.gov NCT00896480),patients received ≤24 doses of… read more here.
Keywords: mage immunotherapeutic; clinical activity; mage; treatment ... See more keywords
Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab
Sign Up to like & getrecommendations! Published in 2019 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-18-3488
Abstract: Purpose: Atezolizumab [anti–programmed death-ligand 1 (PD-L1)] selectively targets PD-L1 to block its interaction with receptors programmed death 1 and B7.1, thereby reinvigorating antitumor T-cell activity. We evaluated the long-term safety and activity of atezolizumab, along… read more here.
Keywords: response; clinical activity; activity; atezolizumab ... See more keywords
Abstract CT083: Clinical activity, immune and molecular correlates of nivolumab vs. nivolumab plus bevacizumab vs nivolumab plus ipilimumab in metastatic renal cell carcinoma
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Research"
DOI: 10.1158/1538-7445.am2017-ct083
Abstract: Background: Immune checkpoint blockade including anti-CTLA-4 (ipilimumab, BMS) and anti-PD1 (nivolumab, BMS) as monotherapies have been known to have clinical activity against metastatic renal cell carcinoma (MRCC), but with relatively low clinical response rate (10-25%).… read more here.
Keywords: immune molecular; clinical activity; nivolumab plus; metastatic renal ... See more keywords
Abstract CT253: Phase 1/2 study of the safety, pharmacokinetics, and preliminary clinical activity of BT7480 in patients with nectin-4 associated advanced malignancies
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-ct253
Abstract: Background: Bicycles are a novel class of synthetic molecules formed by using a central scaffold to constrain short linear peptides into a stabilized bi-cyclic structure, which can then be readily conjugated to other molecules. BT7480… read more here.
Keywords: safety; clinical activity; activity; phase ... See more keywords
Safety and clinical activity of adenosine A2a receptor (A2aR) antagonist, CPI-444, in anti-PD1/PDL1 treatment-refractory renal cell (RCC) and non-small cell lung cancer (NSCLC) patients.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.3004
Abstract: 3004Background: Adenosine production in the tumor leads to immunosuppression through A2aR on infiltrating immune cells. CPI-444 is an oral A2aR antagonist with single agent(SA) anti-tumor activity ... read more here.
Keywords: a2ar antagonist; clinical activity; cell; safety clinical ... See more keywords
Safety and clinical activity of durvalumab monotherapy in patients with hepatocellular carcinoma (HCC).
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.4071
Abstract: 4071Background: Durvalumab, an anti-PD-L1 mAb, has shown early and durable clinical activity with manageable safety in an ongoing Phase 1/2, multicenter, open-label study in pts with advanced solid... read more here.
Keywords: durvalumab monotherapy; clinical activity; activity durvalumab; activity ... See more keywords